Document Information


PMID 16533145  (  )
Title Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
Abstract Although amyotrophic lateral sclerosis (ALS) was described more than 130 years ago, the cause(s) of most cases of this adult motor neuron disease remains a mystery. With the discovery of mutations in one gene (Cu/Zn superoxide dismutase) as a primary cause of some forms of ALS, model systems have been developed that have helped us begin to understand mechanisms involved in motor neuron death and enabled testing of potential new therapies. Several other genes have been implicated as risk factors in motor neuron diseases, including neurofilaments, cytoplasmic dynein and dynactin, vascular endothelial growth factor, and angiogenin. With advances in the basic research of the disease, many hypotheses accounting for motor neuron death are being explored, including loss of trophic support, protein mishandling, mitochondrial dysfunction, excitotoxicity, axonal abnormalities and inflammation. Many of these mechanisms are the focus of research in other neurodegenerative disorders, such as Parkinson's, Alzheimer's and Huntington's disease.

NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.



Targets by SciMiner Summary

HUGO ID Symbol Target Name #Occur ActualStr
12680VEGFAvascular endothelial growth factor A1vascular endothelial growth factor |

 


Targets by SciMiner Full list

HUGO ID Symbol Name ActualStr Score FlankingText
12680VEGFAvascular endothelial growth factor Avascular endothelial growth factor1.0several other genes have been implicated as risk factors in motor neuron diseases including neurofilaments cytoplasmic dynein and dynactin vascular endothelial growth factor and angiogenin.